idb/to..idbe/nas long term growth Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : idb/to..idbe/nas long term growth

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (63)	2/13/2003 10:20:08 AM
From: tuck	Read Replies (1) of 85

ML, defending MEDI, feels that the fact that it takes two FluNsure doses for efficacy confers advantage to FluMist. If the advanced formulation gets it to one, then that advantage goes away, and the market for younger and older folks is still up for grabs, too. Further, if the design of the field study is any different, the one dose regimen still has a chance. Still, that's a lot of "ifs," and ML is definitely correct in pointing out that it's a long way from the market. IDBE flirted with firework status on the open today, despite that note from ML. Worth keeping an eye on in case of weakness. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next